Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

about

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

Item

http://www.wikidata.org/entity/Q47563827

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Outcomes after Allogeneic Stem ...... and Double-Expressor Lymphoma.

@en

Outcomes after Allogeneic Stem ...... and Double-Expressor Lymphoma.

@nl

type

Item

label

Outcomes after Allogeneic Stem ...... and Double-Expressor Lymphoma.

@en

Outcomes after Allogeneic Stem ...... and Double-Expressor Lymphoma.

@nl

prefLabel

Outcomes after Allogeneic Stem ...... and Double-Expressor Lymphoma.

@en

Outcomes after Allogeneic Stem ...... and Double-Expressor Lymphoma.

@nl

P1476

Outcomes after Allogeneic Stem ...... and Double-Expressor Lymphoma.

@en

P2093

Alex F Herrera

http://www.w3.org/2001/XMLSchema#string

Aliyah R Sohani

http://www.w3.org/2001/XMLSchema#string

Amrita Krishnan

http://www.w3.org/2001/XMLSchema#string

Auayporn P Nademanee

http://www.w3.org/2001/XMLSchema#string

Christine Pak

http://www.w3.org/2001/XMLSchema#string

Corey S Cutler

http://www.w3.org/2001/XMLSchema#string

David M Weinstock

http://www.w3.org/2001/XMLSchema#string

Dongyun Yang

http://www.w3.org/2001/XMLSchema#string

Edwin P Alyea

http://www.w3.org/2001/XMLSchema#string

Gabriel K Griffin

http://www.w3.org/2001/XMLSchema#string

P2860

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

P31

scholarly article

P356

10.1016/J.BBMT.2017.11.023

http://www.w3.org/2001/XMLSchema#string

P50

Dennis D Weisenburger

Wing C Chan

P577

2017-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29196080

http://www.w3.org/2001/XMLSchema#string

P932

5826860

http://www.w3.org/2001/XMLSchema#string